AMNI NK003
Alternative Names: AMNI-NK003; HyperTargIPS-NK projectLatest Information Update: 11 Nov 2023
At a glance
- Originator Amniotics
- Class Antineoplastics; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 31 Oct 2023 AMNI NK003 is available for partnering as of 31 Oct 2023. https://www.amniotics.com/rd/pipeline/
- 25 Oct 2022 Preclinical trials in Haematological malignancies in Sweden (Parenteral)
- 25 Oct 2022 Preclinical trials in Solid tumours in Sweden (Parenteral)